Publications by authors named "B Santner"
Objectives: Accurate detection of SARS-CoV-2 RNA is essential to stopping the spread of SARS-CoV-2. The aim of this study was to evaluate the performance of the recently introduced MassARRAY SARS-CoV-2 Panel and to compare it to the cobas SARS-CoV-2 Test.
Methods: The MassARRAY SARS-CoV-2 Panel consists of five assays targeting different sequences of the SARS-CoV-2 genome.
The frequency of clinically relevant transmitted drug resistance mutations (DRMs) against drugs used for 2-drug regimens was 15.6%, but only 2% were not eligible for 1 or more 2-drug regimens. More than 50% of patients harboring any clinically relevant DRMs were found to be part of genetic transmission clusters.
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to compare three rapid molecular tests for detecting influenza A/B RNA in patients with flu-like symptoms who needed hospitalization at Graz University Hospital.
- - Out of 312 samples, the tests from Alere, Roche, and Cepheid showed varying sensitivities (90.5%, 96.0%, and 97.0%) and specificities (99.4%, 97.6%, and 98.2%), with Roche also having a significant number of invalid results.
- - Although the Cepheid test took the longest to provide results (32 minutes), it performed the best overall in accurately detecting influenza virus RNA compared to the other tests evaluated.
Hepatitis C virus (HCV) intergenotypic recombinant forms have been reported for various HCV genotypes/subtypes in several countries worldwide. In a recent study, four patients living in Austria had been identified to be possibly infected with a recombinant HCV strain. To clarify results and determine the point of recombination, full-genome next-generation sequencing using the Illumina MiSeq v2 300 cycle kit (Illumina, San Diego, CA, USA) was performed in the present study.
View Article and Find Full Text PDFBackground: Determination of the hepatitis C virus (HCV) genotype and discrimination between HCV subtypes 1a and 1b is still mandatory prior to anti-HCV treatment initiation. The aim of this study was to evaluate the performance of the recently introduced cobas® HCV GT assay (Roche) and to compare it to two comparator assays.
Methods: The cobas® HCV GT assay is based on primer-specific real-time polymerase chain reaction (PCR).